JOHN W KOZARICH
CIK 1223000 · last filed 2026-06-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$14.10M
Companies
5
Total Filings
104
Lifetime Open-Market Net
-$6.46M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LGND | Director | 42,622 | $293.15 | $12.49M | -$6.63M | 73 | 2026-06-09 |
| Intec Pharma Ltd. (NTEC) Delisted | Director | 151,761 | $9.63 | $1.46M | $45.9K | 2 | 2020-07-17 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 29,000 | — | — | $0 | 5 | 2019-05-10 |
| QLTI | Director | 57,000 | $28.14 | $1.60M | $115.6K | 9 | 2016-06-21 |
| Corium International, Inc. (CORI) Delisted | Director | — | — | — | $0 | 1 | 2014-12-05 |
Recent Filings · Page 5 of 11
104 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-12 | LGND | Grant (A) | +831 | $0 | EDGAR |
| 2019-08-27 | Intec Pharma Ltd. (NTEC) Delisted | Buy (P) | +100,000 | $45.9K | EDGAR |
| 2019-06-07 | LGND | Grant (A) | +835 | $0 | EDGAR |
| 2019-05-14 | LGND | Mixed | — | -$237.6K | EDGAR |
| 2019-05-10 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +2,000 | $0 | EDGAR |
| 2018-10-02 | LGND | Sell (S) | −2,500 | -$687.6K | EDGAR |
| 2018-07-03 | LGND | Sell (S) | −2,500 | -$518.7K | EDGAR |
| 2018-07-03 | LGND | Grant (A) | — | $0 | EDGAR |
| 2018-06-21 | LGND | Grant (A) | +493 | $0 | EDGAR |
| 2018-05-11 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +2,500 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.